Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113917 - TARGET POLYPEPETIDE FOR OSTEOSARCOMA TREATMENT AND APPLICATION THEREOF

Publication Number WO/2020/113917
Publication Date 11.06.2020
International Application No. PCT/CN2019/089086
International Filing Date 29.05.2019
IPC
C07K 7/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
C07K 19/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 2319/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
33fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Applicants
  • 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) SUN YAT-SEN UNIVERSITY CANCER CENTER [CN]/[CN]
Inventors
  • 康铁邦 KANG, Tiebang
  • 廖丹 LIAO, Dan
  • 钟理 ZHONG, Li
  • 沈靖南 SHEN, Jingnan
  • 隋建华 SUI, Jianhua
Agents
  • 广州粤高专利商标代理有限公司 YOGO PATENT & TRADEMARK AGENCY LIMITED COMPANY
Priority Data
201811490126.606.12.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) TARGET POLYPEPETIDE FOR OSTEOSARCOMA TREATMENT AND APPLICATION THEREOF
(FR) POLYPEPTIDE CIBLE POUR LE TRAITEMENT D'OSTÉOSARCOME ET UTILISATION ASSOCIÉE
(ZH) 一种用于治疗骨肉瘤的靶向多肽及其应用
Abstract
(EN)
The present invention discloses a target polypeptide for osteosarcoma treatment and an application thereof. The amino acid sequence of the polypeptide is shown as SEQ ID NO.1 or SEQ ID NO.2. The experiment result in vitro shows that the polypeptide antagonizes the capacity of RAB22A-NeoF1 in promoting osteosarcoma cell adhesion, migration and invasion, and the experiment result in vivo shows that the polypeptide antagonizes the capacity of RAB22A-NeoF1 in promoting osteosarcoma cell transfer, indicating that the polypeptide according to the present invention has greater application prospect in manufacturing medicine for osteosarcoma treatment.
(FR)
La présente invention concerne un polypeptide cible pour le traitement de l'ostéosarcome et une utilisation associée. La séquence d'acides aminés du polypeptide est représentée par SEQ ID NO. 1 ou SEQ ID NO. 2. Des résultats expérimentaux in vitro montrent que le polypeptide a une action antagoniste sur la capacité de RAB22A-NeoF1 dans la promotion de l'adhésion cellulaire de l'ostéosarcome, la migration et l'invasion, et les résultats expérimentaux in vivo montrent que le polypeptide a une action antagoniste sur la capacité de RAB22A-NeoF1 dans la promotion du transfert cellulaire de l'ostéosarcome. Le polypeptide fourni par la présente invention a une grande perspective d'application dans la préparation d'un médicament destiné au traitement de l'ostéosarcome.
(ZH)
本发明公开了一种用于治疗骨肉瘤的靶向多肽及其应用;所述多肽的氨基酸序列如SEQ ID NO.1或SEQ ID NO.2所示;体外实验结果显示,所述多肽能够拮抗RAB22A-NeoF1促进骨肉瘤细胞黏附、迁移以及侵袭的能力;体内实验结果显示,所述多肽能够拮抗RAB22A-NeoF1促进骨肉瘤细胞转移的能力,表明本发明的多肽在制备骨肉瘤治疗药物中具有较大的应用前景。
Also published as
Latest bibliographic data on file with the International Bureau